The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Targeting STAT3 in cancer: how successful are we?
Open accessAbstract
BACKGROUND: Aberrant activation of the signal transducer and activator of transcription (STAT)3 occurs in many human tumors. Moreover, studies utilizing genetic and pharmacological approaches to modulate constitutive STAT3 activity have provided compelling evidence for the critical role of aberrant STAT3 activity in malignant transformation and tumor progression, and thereby validated STAT3 as a novel cancer drug target. OBJECTIVE: This review is intended to be a full coverage of the efforts to develop direct STAT3 inhibitors and will provide a discussion on the inhibitory modalities developed to date. METHODS: Review of the literature focused on the modalities and mechanisms that directly target and inhibit the STAT protein or its functions. RESULTS/CONCLUSION: While a variety of STAT3 inhibitors have been identified that induce antitumor cell effects in vitro and in vivo, the landscape remains murky. With a few exceptions, most of the STAT3 inhibitors reported to date have not undergone an in vivo efficacy, pharmacology or toxicity testing. Also, there is no evidence, per the published literature of an impending clinical development for the few agents that were reported to exhibit in vivo efficacy. Overall, there is the need for a reassessment of the ongoing strategies to target STAT3 intended not only for refinement, but also for incorporating some new technologies to strengthen our efforts and ensure the success - sooner, rather than later - of identifying suitable anti-STAT3 agents for development into clinically useful anticancer therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Al‐Assar, O., & Crouch, D. H. (2005) · Molecular Cancer · doi:10.1186/1476-4598-4-13 · Cited by 80
RetractedDarnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278 · cited 5×
“Moreover, aberrant STAT3 promotes invasion and metastasis, thereby contributing to tumor progression [2,6-9] .”
BackgroundInfluentialBowman, T., Garcia, R., Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203527 · Cited by 1,743 · cited 1×
“Since then, a large number of studies have been undertaken for the validation of STAT3 as a cancer drug target [2,9,75,76] , and substantial efforts have poured into the discovery of novel STAT3 inhibitors [e.”
BackgroundSelf-citationRegulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells
Wang, T., Niu, G., Kortylewski, M., Burdelya, L., Shain, K., Zhang, S., Bhattacharya, R., Gabrilovich, D., Heller, R., Coppola, D., et al. (2004) · Nature Medicine · doi:10.1038/nm976 · Cited by 1,155
Stattic: a small-molecule inhibitor of STAT3 activation and dimerization
Schust, J., Sperl, B., Hollis, A., Mayer, T. U., & Berg, T. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.09.018 · Cited by 1,105
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity
Kortylewski, M., Kujawski, M., Wang, T., Wei, S., Zhang, S., Pilon-Thomas, S., Niu, G., Kay, H., Mulé, J., Kerr, W. G., et al. (2005) · Nature Medicine · doi:10.1038/nm1325 · Cited by 1,031
Enhanced DNA-Binding Activity of a Stat3-Related Protein in Cells Transformed by the Src Oncoprotein
Yu, C.-L., Meyer, D. J., Campbell, G. S., Larner, A. C., Carter-Su, C., Schwartz, J., & Jove, R. (1995) · Science · doi:10.1126/science.7541555 · Cited by 931
Three-dimensional structure of the Stat3β homodimer bound to DNA
Becker, S., Groner, B., & Müller, C. W. (1998) · Nature · doi:10.1038/28101 · Cited by 788
Siddiquee, K., Zhang, S., Guida, W. C., Blaskovich, M. A., Greedy, B., Lawrence, H. R., Yip, M. L. R., Jove, R., McLaughlin, M. M., Lawrence, N. J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609757104 · Cited by 736
Self-citationBlaskovich, M. A., Sun, J., Cantor, A. B., Turkson, J., Jove, R., & Sebti, S. M. (2003) · PubMed · Cited by 643
Self-citationBharti, A. C., Donato, N., & Aggarwal, B. B. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.7.3863 · Cited by 508
Song, H., Wang, R., Wang, S., & Lin, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409894102 · Cited by 504
STAT3 as a target for inducing apoptosis in solid and hematological tumors
Al Zaid Siddiquee, K., & Turkson, J. (2008) · Cell Research · doi:10.1038/cr.2008.18 · Cited by 487
Self-citationTurkson, J., Ryan, D., Kim, J. S., Zhang, Y., Chen, Z., Haura, E., Laudano, A., Sebti, S., Hamilton, A. D., & Jove, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107527200 · Cited by 448
Self-citationHaura, E. B., Turkson, J., & Jove, R. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0195 · Cited by 430
Self-citationAGGARWAL, B. B., SETHI, G., AHN, K. S., SANDUR, S. K., PANDEY, M. K., KUNNUMAKKARA, A. B., SUNG, B., & ICHIKAWA, H. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1378.063 · Cited by 398
Iwamaru, A., Szymanski, S., Iwado, E., Aoki, H., Yokoyama, T., Fokt, I., Hess, K., Conrad, C., Madden, T., Sawaya, R., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210031 · Cited by 370
STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-α3
Liu, L., McBride, K. M., & Reich, N. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501643102 · Cited by 348
Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth
Leong, P. L., Andrews, G. A., Johnson, D. E., Dyer, K. F., Xi, S., Mai, J. C., Robbins, P. D., Gadiparthi, S., Burke, N. A., Watkins, S. F., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0534764100 · Cited by 340
Nefedova, Y., Nagaraj, S., Rosenbauer, A., Muro-Cacho, C., Sebti, S. M., & Gabrilovich, D. I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0529 · Cited by 318
Levitzki, A. (1992) · The FASEB Journal · doi:10.1096/fasebj.6.14.1426765 · Cited by 317
Validating Stat3 in cancer therapy
Darnell, J. E. (2005) · Nature Medicine · doi:10.1038/nm0605-595 · Cited by 307
STAT proteins as novel targets for cancer drug discovery
Turkson, J. (2004) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.8.5.409 · Cited by 295
Self-citationIndirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells
Nam, S., Buettner, R., Turkson, J., Kim, D., Cheng, J. Q., Muehlbeyer, S., Hippe, F., Vatter, S., Merz, K.-H., Eisenbrand, G., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409467102 · Cited by 294
Self-citationBhattacharya, S., Ray, R. M., & Johnson, L. R. (2005) · Biochemical Journal · doi:10.1042/bj20050465 · Cited by 291
Natarajan, C., & Bright, J. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.12.6506 · Cited by 288
Kotha, A., Sekharam, M., Cilenti, L., Siddiquee, K., Khaled, A., Zervos, A. S., Carter, B., Turkson, J., & Jove, R. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0268 · Cited by 283
Self-citationPardanani, A., Hood, J., Lasho, T., Levine, R. L., Martin, M. B., Noronha, G., Finke, C., Mak, C. C., Mesa, R., Zhu, H., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404750 · Cited by 272
Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity
Sun, J., Blaskovich, M. A., Jove, R., Livingston, S. K., Coppola, D., & Sebti, S. M. (2005) · Oncogene · doi:10.1038/sj.onc.1208470 · Cited by 263
Curcumin and resveratrol inhibit nuclear factor-kappaB-mediated cytokine expression in adipocytes
Gonzales, A. M., & Orlando, R. A. (2008) · Nutrition & Metabolism · doi:10.1186/1743-7075-5-17 · Cited by 260
Turkson, J., Kim, J. S., Zhang, S., Yuan, J., Huang, M., Glenn, M., Haura, E., Sebti, S., Hamilton, A. D., & Jove, R. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.261.3.3 · Cited by 255
Self-citationKnockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells
Konnikova, L., Kotecki, M., Kruger, M. M., & Cochran, B. H. (2003) · BMC Cancer · doi:10.1186/1471-2407-3-23 · Cited by 217
Tannin-Spitz, T., Grossman, S., Dovrat, S., Gottlieb, H. E., & Bergman, M. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.09.012 · Cited by 216
Ling, X., & Arlinghaus, R. B. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2425 · Cited by 201
Turkson, J., Zhang, S., Palmer, J., Kay, H., Stanko, J., Mora, L. B., Sebti, S., Yu, H., & Jove, R. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1533.3.12 · Cited by 188
Self-citationSiddiquee, K. A. Z., Gunning, P. T., Glenn, M., Katt, W. P., Zhang, S., Schroeck, C., Sebti, S. M., Jove, R., Hamilton, A. D., & Turkson, J. (2007) · ACS Chemical Biology · doi:10.1021/cb7001973 · Cited by 187
Self-citationTargeting Bcl-2 and Bcl-X with nonpeptidic small-molecule antagonists
WANG, S. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.015 · Cited by 175
Xi, S., Gooding, W. E., & Grandis, J. R. (2005) · Oncogene · doi:10.1038/sj.onc.1208316 · Cited by 170
Turkson, J., Zhang, S., Mora, L. B., Burns, A. C., Sebti, S. M., & Jove, R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502694200 · Cited by 169
Self-citationMohammad, R. M., Goustin, A. S., Aboukameel, A., Chen, B., Banerjee, S., Wang, G., Nikolovska‐Coleska, Z., Wang, S., & Al-Katib, A. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1574 · Cited by 157
Paradigm shifts in the cell biology of STAT signaling
Sehgal, P. B. (2008) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2008.07.003 · Cited by 149
Mackenzie, G. G., Queisser, N., Wolfson, M. L., Fraga, C. G., Adamo, A. M., & Oteiza, P. I. (2008) · International Journal of Cancer · doi:10.1002/ijc.23477 · Cited by 144
Coleman, Ren, Z., Mandal, P. K., Cameron, A. G., Dyer, G. A., Muranjan, S., Campbell, M. L., Chen, X., & McMurray, J. S. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050513m · Cited by 141
Nagel‐Wolfrum, K., Buerger, C., Wittig, I., Butz, K., Hoppe‐Seyler, F., & Groner, B. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.170.2.3 · Cited by 133
Jing, N., Li, Y., Xiong, W., Sha, W., Jing, L., & Tweardy, D. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-4041 · Cited by 132
Gao, L., Zhang, L., Hu, J., Li, F., Shao, Y., Zhao, D., Kalvakolanu, D. V., Kopecko, D. J., Zhao, X., & Xu, D.-Q. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0148 · Cited by 131
Identification of a High-Affinity Phosphopeptide Inhibitor of Stat3
Ren, Z., Cabell, L. A., Schaefer, T. S., & McMurray, J. S. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)01050-8 · Cited by 128
Ferrajoli, A., Faderl, S. H., Van, Q., Koch, P. E., Harris, D., Liu, Z., Hazan‐Halevy, I., Wang, Y., Kantarjian, H. M., Priebe, W., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0593 · Cited by 128
Cell-to-cell adhesion modulates Stat3 activity in normal and breast carcinoma cells
Vultur, A., Cao, J., Arulanandam, R., Turkson, J., Jove, R., Greer, P. A., Craig, A. W., Elliott, B. E., & Raptis, L. H. (2004) · Oncogene · doi:10.1038/sj.onc.1207378 · Cited by 126
Self-citationSon, G., Iimuro, Y., Seki, E., Hirano, T., Kaneda, Y., & Fujimoto, J. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00185.2007 · Cited by 125
Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice
Zhang, X., Zhang, J., Wang, L., Wei, H., & Tian, Z. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-149 · Cited by 116
A New Small-Molecule Stat3 Inhibitor
McMurray, J. S. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.11.001 · Cited by 106
Fletcher, S., Turkson, J., & Gunning, P. T. (2008) · ChemMedChem · doi:10.1002/cmdc.200800123 · Cited by 105
Self-citationStat3 as a Potential Target for Cancer Immunotherapy
Kortylewski, M., & Yu, H. (2007) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211327.76266.65 · Cited by 98
Targeting Stat3 with G-Quartet Oligodeoxynucleotides in Human Cancer Cells
Jing, N., Li, Y., Xu, X., Sha, W., Li, P., Feng, L., & Tweardy, D. J. (2003) · DNA and Cell Biology · doi:10.1089/104454903770946665 · Cited by 96
Weerasinghe, P., Garcia, G., Zhu, Q., Yuan, P., Feng, L., Mao, L., & Jing, N. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.1.129 · Cited by 95 · cited 2×
“The application of T40214 in vivo at 5 – 10 mg/kg every 2 days in tumor xenografts of human breast, lung, prostate, head and neck cancer cell lines markedly inhibited STAT3-mediated gene transcription and induced tumor cell apoptosis and tumor regression [13,14,51] .”
BackgroundBuerger, C., Nagel‐Wolfrum, K., Kunz, C., Wittig, I., Butz, K., Hoppe‐Seyler, F., & Groner, B. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301629200 · Cited by 94
Chen, C., Loy, A., Cen, L., Chan, C., Hsieh, F.-C., Cheng, G., Wu, B., Qualman, S. J., Kunisada, K., Yamauchi‐Takihara, K., et al. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-111 · Cited by 91
Jing, N., Zhu, Q., Yuan, P., Li, Y., Mao, L., & Tweardy, D. J. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0302 · Cited by 91
Design, synthesis, and studies of small molecule STAT3 inhibitors
Bhasin, D. K., Cisek, K. K., Pandharkar, T., Regan, N., Li, C., Pandit, B., Lin, J., & Li, P. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.10.031 · Cited by 88
Hellsten, R., Johansson, M., Dahlman, A., Dizeyi, N., Sterner, O., & Bjartell, A. S. (2007) · The Prostate · doi:10.1002/pros.20699 · Cited by 84
Su, Y., Li, G., Zhang, X., Gu, J., Zhang, C., Tian, Z., & Zhang, J. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.8.6263 · Cited by 83
Cucurbitacin I inhibits Stat3 and induces apoptosis in Sézary cells.
van Kester, M., Out-Luiting, J., Borne, P. V. D., Willemze, R., Tensen, C., & Vermeer, M. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701246 · Cited by 82
Rationally Designed Inhibitors Identify STAT3 N-Domain as a Promising Anticancer Drug Target
Timofeeva, O. A., Gaponenko, V., Lockett, S., Tarasov, S. G., Jiang, S., Michejda, C. J., Perantoni, A. O., & Tarasova, N. I. (2007) · ACS Chemical Biology · doi:10.1021/cb700186x · Cited by 80
Sun, X., Zhang, J., Wang, L., & Tian, Z. (2008) · Cancer Letters · doi:10.1016/j.canlet.2007.12.009 · Cited by 80
Shi, X., Franko, B., Frantz, C., Amin, H. M., & Lai, R. L. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06259.x · Cited by 80
Inhibition of interleukin‐6 signaling by galiellalactone
Weidler, M., Rether, J., Anke, T., & Erkel, G. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)02115-3 · Cited by 79
Combined antitumor activity of cucurbitacin B and docetaxel in laryngeal cancer
Liu, T., Zhang, M., Zhang, H., Sun, C., Yang, X., Deng, Y., & Ji, W. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.03.032 · Cited by 69
Barton, B. E., Murphy, T. F., Shu, P., Huang, H. F. S., Meyenhofen, M., & Barton, A. B. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1183.3.10 · Cited by 55
Transcription Factor Oligodeoxynucleotides to NF-κB Inhibit Transcription of IL-8 in Bronchial Cells
Bezzerri, V., Borgatti, M., Nicolis, E., Lampronti, I., Dechecchi, M. C., Mancini, I., Rizzotti, P., Gambari, R., & Cabrini, G. (2008) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2007-0176oc · Cited by 52
Moriyama, I., Ishihara, S., Rumi, M. A. K., Aziz, M., Mishima, Y., Oshima, N., Kadota, C., Kadowaki, Y., Amano, Y., & Kinoshita, Y. (2008) · Laboratory Investigation · doi:10.1038/labinvest.2008.38 · Cited by 49
Borghouts, C., Kunz, C., Delis, N., & Groner, B. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0245 · Cited by 46
Schröder, M., Kroeger, K. M., Volk, H., Eidne, K. A., & Grütz, G. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.1003496 · Cited by 41
Transcription Factors as Molecular Targets: Molecular Mechanisms of Decoy ODN and their Design
Tomita, N., Ogihara, T., & Morishita, R. (2003) · Current Drug Targets · doi:10.2174/1389450033490803 · Cited by 38
Discovery of the catechol structural moiety as a Stat3 SH2 domain inhibitor by virtual screening
Hao, W., Hu, Y., Niu, C., Huang, X., Chang, C.-P. B., Gibbons, J. J., & Xu, J. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.08.032 · Cited by 37
Indirubin-3′-monoxime, a derivative of a Chinese anti-leukemia medicine, inhibits Notch1 signaling
Lee, M.-J., Kim, M., Mo, J., Ann, E., Seo, M., Hong, J., Kim, Y., & Park, H.-S. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.02.013 · Cited by 29
Computational study on mechanism of G-quartet oligonucleotide T40214 selectively targeting Stat3
Zhu, Q., & Jing, N. (2007) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-007-9147-6 · Cited by 25
Inhibition of normal lymphocyte proliferation by Indirubin-3′-monoxime: A multifactorial process
Kagialis‐Girard, S., Mialou, V., Chebel, A., Chien, W. W., Tigaud, I., Mokdad, F., Badiou, C., & Ffrench, M. (2007) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190601059696 · Cited by 12
Cited by
NF-κB and STAT3 – key players in liver inflammation and cancer
He, G., & Karin, M. (2011) · Cell Research · doi:10.1038/cr.2010.183 · Cited by 1,197
JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease
O'Shea, J. J., & Plenge, R. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.014 · Cited by 1,138
Role of interleukin-6 in cancer progression and therapeutic resistance
Kumari, N., Dwarakanath, B. S., Das, A., & Bhatt, A. N. (2016) · Tumor Biology · doi:10.1007/s13277-016-5098-7 · Cited by 1,092
Kim, E., Kim, M., Woo, D.-H., Shin, Y., Shin, J., Chang, N., Oh, Y. T., Kim, H., Rheey, J., Nakano, I., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.008 · Cited by 806
Constitutive activation of STAT 3 in breast cancer cells: A review
Banerjee, K., & Resat, H. (2016) · International Journal of Cancer · doi:10.1002/ijc.29923 · Cited by 611
Metadata
- Authors
- Yue, P., & Turkson, J.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2008-11-21
- Volume
- 18
- Issue
- 1
- Pages
- 45-56
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2132047377
- Cited by
- 413
- References
- 79
- FWCI
- 9.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.